Investor Ideas #Potcasts; #Cannabis News and Stocks on the Move; TSX: $APH.TO, TSXV: $EMC.V, TSXV: $LVWL.V, CSE: $KBEV.C, TSXV: $TBP.V
July 26th Potcast sponsored by Lexaria Bioscience Corp. (CSE: $LXX.C) (OTC: $LXRP)
Delta, Kelowna, BC - July 26, 2018 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its "potcast' site, www.potcasts.ca release today's edition of its series, Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: TSX:APH, TSXV: EMC, TSXV: LVWL, CSE: KBEV, TSXV: TBP
Today's podcast overview/transcript:
Good morning and welcome to another Investorideas.com potcast ; looking at cannabis news, stocks to watch as well as insights from thought leaders and experts.
Today's potcast was sponsored by Kelowna based Lexaria Bioscience Corp trading on the CSE under symbol LXX and on the OTC as LXRP. Lexaria has developed a new disruptive drug delivery platform: DehydraTECH The Company's patented technology changes the way Active Pharmaceutical Ingredients ("APIs") enter the body orally:
1) Masks unwanted tastes - eliminates the need for sugar-filled edibles.
2) Reduces time of onset - effects are felt within 15-20 min vs. 60-120 min.
3) Avoids first-pass liver metabolism
4) Increases bio-absorption by 5-10X
The Company's DehydraTECH™ technology is patent-protected for multiple APIs: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, Nicotine and Fat soluble vitamins.
Learn more about Lexaria at www.lexariabioscience.com
Today's podcast features news announcements from Aphria Inc. trading on the TSX as APH and US OTC as APHQF, Emblem Corp. trading on the TSX-Venture as EMC, LIVEWELL CANADA INC. trading on the TSX-Venture as LVWL, Koios Beverage Corp. trading on the CSE as KBEV and the OTC as SNOVF and Tetra Bio-Pharma Inc., trading on the TSX-VENTURE as TBP and the OTCQB as TBPMF.
Aphria Inc. today announced that it completed its largest international shipment of cannabis oil to date to Australian medical life science company, Medlab Clinical Limited ("Medlab"). The shipment is part of the previously announced agreement between Aphria and Medlab in which Aphria produces and supplies high-yield cannabis extracts for Medlab to be used in a human trial to test the management of intractable pain in oncology patients - the first trial of its kind globally.
For the purposes of the clinical trial, Aphria has provided a high-CBD cannabis oil and a high-THC cannabis oil, both of which were designed specifically for Medlab. Once at Medlab, the products are then combined with Medlab's patented medicine delivery system, NanoCelle™. Medlab's clinical trial is posited to provide an effective and efficacious pain therapy targeted to advanced cancer pain, that rivals standard opioid use. The product formulation, manufacturing, and final product validation have met the TGO93 standard set by the Australian Therapeutic Goods Administration ("TGA") and permits have been approved by Health Canada.
Emblem Corp. announced today that it has signed a non-binding Letter of Intent ("LOI") to acquire all of the issued and outstanding securities in Natura Naturals Inc. ("Natura") that it does not already own for $25 million in cash, $12.5 million in mortgage financing and 26,102,941 common shares of Emblem. Based on Emblem's 45 day VWAP of $1.36, the implied transaction value is $76 million (inclusive of Natura shares already owned by Emblem). On completion of the Transaction, Emblem will further its aggressive approach to sales growth both domestically and internationally backed by robust supply from the Natura greenhouse.
Based in Leamington, Ontario, Natura operates a 662,000 sq ft licensed greenhouse that is currently undergoing a phased conversion and retrofit that is expected to bring up to 15,000 kg of annualized cannabis production online in 2018. Once completed in 2019, the facility is expected to bring total annualized cannabis production capacity to approximately 70,000 kg per year.
The entering into of the LOI follows Emblem's recently announced $3 million equity investment in Natura and the entering into of a 3,000 kg per year supply agreement.
LIVEWELL CANADA INC. greeted favourably the interest of the Government of Québec in participating in the financing of its world-class Research and Innovation Centre in Litchfield, in Pontiac RCM, Québec.
The Government of Québec, through the Ministère de l'Économie, de la Science et de l'Innovation of Québec (MESI) and in collaboration with Investissement Québec, recently sent the Company a letter of interest stating that it is open to contributing up to 25% of the overall financing of the project, subject to terms to be determined in the near future.
The President of LiveWell Canada, Mr. David Rendimonti, expressed his great satisfaction in this offer of collaboration from the Government of Québec. "This is a great step in our quest to develop new therapeutic and medical solutions thanks to a world-class Research and Innovation Centre on hemp and cannabis," he said.
Koios Beverage Corp. announced that the first flavour of its new and improved line of functional cognitive enhancing beverages, Pear Guava, is now available for purchase.
Customers in both Canada and the United States can order the drink online from the company's website https://www.mentaltitan.com/product/pear-guava/ It is also available for purchase through Koios's large distribution network, which includes retailers such as SportLife Distribution, Max Muscle, and soon-to-be available through Amazon online.
The new formula enhances Koios's proprietary blend of nootropics by adding super foods such as Lion's Mane Mushroom, a powerful ingredient recognized for enhancing brain function, which Whole Foods recently listed as a trending ingredient in its annual functional ingredients guide.
"We have created the first drink of its kind," says CEO Chris Miller, who founded the company in part because of his own personal experience with a mental-health disorder, ADHD. The Global Brain Health market is expected to grow by a CAGR of 20 per cent to $11.6 billion by 2024, and we are excited to be innovating in the space and creating products that consumers are looking for.
Koios recently launched a wholly owned subsidiary, Cannavated Beverages Co. to develop a line of cannabis infused, brain-healthy drinks for the legal marijuana market.
Koios is also one of the only drinks in the world to infuse its products with MCT oil. MCT oil is derived from coconuts and has been shown to help the body burn fat more effectively, create lasting energy from a natural food source, produce ketones in the brain, allowing for greater brain function and clarity, support healthy hormone production and improve immunity.
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development today announced that it received two meeting granted letters from the United States Food and Drug Administration (FDA), for Type B and C meetings, to discuss requirements for obtaining marketing approval under the 505(b)(2) regulatory pathway for its dronabinol AdVersa™ mucoadhesive product, PPP002.
Tetra, along with its partner IntelGenx Corp, is developing this product in the USA under the accelerated 505(b)(2) pathway for chemotherapy-induced nausea and vomiting and anorexia and weight loss in people with AIDS (the same indications that have already been approved for Marinol®). The 505(b)(2) speciality Contract Research Organization, Camargo, is guiding the regulatory submissions to the FDA. The corporation is also developing PPP002 in Canada as an adjunct therapy for opioid reduction in patients with chronic pain.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. www.lexariabioscience.com
Subscribe to the new cannabis podcast series:
To hear more Investorideas.com podcasts visit: http://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Google Play Music, Stitcher and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Ideas
Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, company profiles, interviews and more in leading sectors.
Investorideas.com cannabis/marijuana and hemp content now includes http://cannabisstocknews.blogspot.com on Blogger.com: the Investorideas.com news and stock directory pages, a cannabis investor group on Linkedin.com , the 420 Cannabis Investor ideas www.420cannabisinvestorideas.com, and the new AI site Global Cannabis Investing at www.Globalcannabisinvesting.com
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure Lexaria Bioscience Corp. ( CSE: LXX) (OTC: LXRP) is a media sponsor of the podcast starting July 5 2018 more info http://www.investorideas.com/About/News/Clientspecifics.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Follow us on Social Media
Do you trade or invest in Marijuana / Hemp Stocks? Check out our stock directory of publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana / Hemp Stocks
Join our Group on Linkedin and talk about - Marijuana / Hemp Stocks - News and Trends in Green Investing